Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Lates News:
-
Amidst Hawkish Fed Hints, Markets Wary Of Jobs Data
-
Masonite To Buy PGT Innovations In $3 Bln Cash, Stock Deal
-
Michael Saylor: ‘Bitcoin Must Be Understood As Something Outside This Crypto Industry’
-
Market Trends At This Hour
-
$BTC: BlackRock ‘Seeing Substantial Interest From Some Institutional Clients’